免疫学
免疫抑制
爱泼斯坦-巴尔病毒
淋巴增殖性病變
免疫系统
爱泼斯坦-巴尔病毒感染
病毒
恶性肿瘤
人口
移植后淋巴增生性疾病
无症状的
向性
伽马赫氏病毒亚科
医学
疱疹病毒科
病毒学
生物
淋巴瘤
病毒性疾病
病理
环境卫生
作者
Olivia M. Martinez,Sheri M. Krams
出处
期刊:Transplantation
[Ovid Technologies (Wolters Kluwer)]
日期:2017-09-01
卷期号:101 (9): 2009-2016
被引量:47
标识
DOI:10.1097/tp.0000000000001767
摘要
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication in organ transplant recipients and is most often associated with the Epstein Barr virus (EBV). EBV is a common gammaherpes virus with tropism for B lymphocytes and infection in immunocompetent individuals is typically asymptomatic and benign. However, infection in immunocompromised or immunosuppressed individuals can result in malignant B cell lymphoproliferations, such as PTLD. EBV+ PTLD can arise after primary EBV infection, or because of reactivation of a prior infection, and represents a leading malignancy in the transplant population. The incidence of EBV+ PTLD is variable depending on the organ transplanted and whether the recipient has preexisting immunity to EBV but can be as high as 20%. It is generally accepted that impaired immune function due to immunosuppression is a primary cause of EBV+ PTLD. In this overview, we review the EBV life cycle and discuss our current understanding of the immune response to EBV in healthy, immunocompetent individuals, in transplant recipients, and in PTLD patients. We review the strategies that EBV uses to subvert and evade host immunity and discuss the implications for the development of EBV+ PTLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI